81. Tyramine induces release of noradrenaline from adrenergic nerve endings
(a) By depolarizing the axonal membrane
(b) By mobilizing Ca2+
(c) By a nonexocytotic process
(d) Only in the presence of MAO inhibitors
Ans: C
82. Choose the correct statement from the following about a1 – adrenergic receptor agonists
(a) Norepinephrine > isoproterenol > epinephrine
(b) Norepinephrine < epinephrine > isoproterenol
(c) Epinephrine = norepinephrine >> isoproterenol
(d) Epinephrine > isoproterenol > norepinephrine
Ans: C
83. A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is
(a) Ephedrine
(b) Dopamine
(c) Isoprenaline
(d) Tyramine
Ans: D
84. Low doses of adrenaline dilate the following vascular bed
(a) Cutaneous
(b) Mucosal
(c) Renal
(d) Skeletal muscle
Ans: D
85. a2–adrenergic receptors are associated with following except
(a) Increase in phospholipase C activity
(b) Increase in potassium channel conductance
(c) Decrease in calcium channel conductance
(d) Increase in adenylyl cyclase activity
Ans: D
86. Adrenaline raises blood glucose level by the following actions except
(a) Inducing hepatic glycogenolysis
(b) Inhibiting insulin secretion from pancreatic ß cells
(c) Augmenting glucagons secretion from pancreatic a cells
(d) Inhibiting peripheral glucose utilization
Ans: D
87. Noradrenaline is administered by
(a) Subcutaneous injection
(b) Intramuscular injection
(c) Slow intravenous infusion
(d) All of the above routes
Ans: C
88. Dobutamine differs from dopamine in that
(a) It does not activate peripheral dopaminergic receptors
(b) It does not activate adrenergic ß receptors
(c) It causes pronounced tachycardia
(d) It has good blood-brain barrier penetrability
Ans: A
89. Ephedrine is similar to adrenaline in the following feature
(a) Potency
(b) Inability to penetrate blood-brain barrier
(c) Duration of action
(d) Producing both a and ß adrenergic effects
Ans: D
90. Continuous exposure of ctecholaminesensitive cells and tissues to adrenergic agonists causes a progressive diminition in their capacity to respond, this
phenomenon is called as
(a) Refractoriness
(b) Desensitization
(c) Tachyphylaxis
(d) All of the above
Ans: D
More Questions & Answers:-
Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9
Page10
(a) By depolarizing the axonal membrane
(b) By mobilizing Ca2+
(c) By a nonexocytotic process
(d) Only in the presence of MAO inhibitors
Ans: C
82. Choose the correct statement from the following about a1 – adrenergic receptor agonists
(a) Norepinephrine > isoproterenol > epinephrine
(b) Norepinephrine < epinephrine > isoproterenol
(c) Epinephrine = norepinephrine >> isoproterenol
(d) Epinephrine > isoproterenol > norepinephrine
Ans: C
83. A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is
(a) Ephedrine
(b) Dopamine
(c) Isoprenaline
(d) Tyramine
Ans: D
84. Low doses of adrenaline dilate the following vascular bed
(a) Cutaneous
(b) Mucosal
(c) Renal
(d) Skeletal muscle
Ans: D
85. a2–adrenergic receptors are associated with following except
(a) Increase in phospholipase C activity
(b) Increase in potassium channel conductance
(c) Decrease in calcium channel conductance
(d) Increase in adenylyl cyclase activity
Ans: D
86. Adrenaline raises blood glucose level by the following actions except
(a) Inducing hepatic glycogenolysis
(b) Inhibiting insulin secretion from pancreatic ß cells
(c) Augmenting glucagons secretion from pancreatic a cells
(d) Inhibiting peripheral glucose utilization
Ans: D
87. Noradrenaline is administered by
(a) Subcutaneous injection
(b) Intramuscular injection
(c) Slow intravenous infusion
(d) All of the above routes
Ans: C
88. Dobutamine differs from dopamine in that
(a) It does not activate peripheral dopaminergic receptors
(b) It does not activate adrenergic ß receptors
(c) It causes pronounced tachycardia
(d) It has good blood-brain barrier penetrability
Ans: A
89. Ephedrine is similar to adrenaline in the following feature
(a) Potency
(b) Inability to penetrate blood-brain barrier
(c) Duration of action
(d) Producing both a and ß adrenergic effects
Ans: D
90. Continuous exposure of ctecholaminesensitive cells and tissues to adrenergic agonists causes a progressive diminition in their capacity to respond, this
phenomenon is called as
(a) Refractoriness
(b) Desensitization
(c) Tachyphylaxis
(d) All of the above
Ans: D
More Questions & Answers:-
Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9
Page10
No comments:
Post a Comment